clinical trial · NCT05772273
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
The First Affiliated Hospital of Soochow University·N/A·recruiting·n = 43
Acute Myeloid LeukemiaAzacitidineDonor lymphocyte infusionCamrelizumab
brief summary
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
started
Mar 15, 2023
primary completion
Jul 1, 2026
completion
Dec 31, 2026
last updated
Nov 21, 2025
official title
Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol